Evelo Biosciences, Inc.
DelistedCIK 1694665fmd_06R2NF01HGHNHGYA2ARE2HMZ24Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2023, 28 periods
Latest annual · FY2022
Millions- Operating income
- (108)
- Net income
- (115)
- Free cash flow
- (102)
Latest quarter · Q3 FY2023
Millions- Operating income
- (11)
- Net income
- (12)
- Free cash flow
- (10)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2017 to FY2022
- n/m
Evelo Biosciences, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$108.5 million | -$115.4 million | 10-K 2023-03-16 · proof | |
| Net income | -$114.5 million | -$122.2 million | 10-K 2023-03-16 · proof | |
| Cash from operating activities | -$101.2 million | -$96.7 million | 10-K 2023-03-16 · proof | |
| Free cash flow | -$101.9 million | -$98.2 million | 10-K 2023-03-16 · proof | |
| Total assets | $64.4 million | $87.9 million | -26.7% | 10-K 2023-03-16 · proof |
| Total liabilities | $69.4 million | $79.2 million | -12.3% | 10-K 2023-03-16 · proof |
| Cash and cash equivalents | $47.9 million | $68.4 million | -30% | 10-K 2023-03-16 · proof |
| Total debt | $43.6 million | $46.6 million | -6.3% | 10-Q 2023-05-15 · proof |
- What was Evelo Biosciences, Inc.'s operating income in fiscal 2022?
- Evelo Biosciences, Inc. reported operating income of -$108.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$115.4 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What was Evelo Biosciences, Inc.'s net income in fiscal 2022?
- Evelo Biosciences, Inc. reported net income of -$114.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$122.2 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What was Evelo Biosciences, Inc.'s cash from operating activities in fiscal 2022?
- Evelo Biosciences, Inc. reported cash from operating activities of -$101.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$96.7 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What was Evelo Biosciences, Inc.'s free cash flow in fiscal 2022?
- Evelo Biosciences, Inc. reported free cash flow of -$101.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$98.2 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What are Evelo Biosciences, Inc.'s total assets?
- As of Dec 31, 2022, Evelo Biosciences, Inc. reported total assets of $64.4 million, against $87.9 million a year earlier (-26.7%). Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What are Evelo Biosciences, Inc.'s total liabilities?
- As of Dec 31, 2022, Evelo Biosciences, Inc. reported total liabilities of $69.4 million, against $79.2 million a year earlier (-12.3%). Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What are Evelo Biosciences, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Evelo Biosciences, Inc. reported cash and cash equivalents of $47.9 million, against $68.4 million a year earlier (-30%). Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What is Evelo Biosciences, Inc.'s total debt?
- As of Dec 31, 2022, Evelo Biosciences, Inc. reported total debt of $43.6 million, against $46.6 million a year earlier (-6.3%). Source: the 10-Q filed with the SEC on May 15, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1694665&period_type=annual&limit=5"Information only, not investment advice.